Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) have been assigned an average recommendation of “Buy” from the nine analysts that are covering the stock, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $9.56.
Several equities research analysts have recently commented on the company. Royal Bank of Canada raised MannKind from a “sector perform” rating to an “outperform” rating and boosted their price target for the stock from $7.00 to $10.00 in a research note on Thursday, December 19th. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of MannKind in a research report on Thursday, February 27th. StockNews.com upgraded shares of MannKind from a “hold” rating to a “buy” rating in a research report on Wednesday, March 19th. Wells Fargo & Company started coverage on MannKind in a report on Friday, December 20th. They issued an “overweight” rating and a $9.00 price target for the company. Finally, Mizuho started coverage on MannKind in a research note on Thursday. They set an “outperform” rating and a $12.00 price objective on the stock.
View Our Latest Research Report on MNKD
Institutional Inflows and Outflows
MannKind Price Performance
MannKind stock opened at $4.66 on Thursday. MannKind has a 1-year low of $3.97 and a 1-year high of $7.63. The stock’s 50 day moving average price is $5.20 and its 200 day moving average price is $6.07. The company has a market cap of $1.42 billion, a PE ratio of 66.57 and a beta of 1.22.
MannKind (NASDAQ:MNKD – Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.03. The business had revenue of $76.78 million during the quarter, compared to the consensus estimate of $74.99 million. MannKind had a net margin of 8.07% and a negative return on equity of 17.74%. On average, equities research analysts anticipate that MannKind will post 0.1 EPS for the current fiscal year.
About MannKind
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
Further Reading
- Five stocks we like better than MannKind
- What Are Dividend Achievers? An Introduction
- Robinhood Strategies Could Be a Game-Changer for Young Investors
- What Does Downgrade Mean in Investing?
- Are These 3 Retail Stocks Oversold or Really in Trouble?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.